Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on August 6, 2018. The filing serves to announce the company's financial results for the quarter ended June 30, 2018, which are detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2018.
Guidance, Outlook, and Risks
The filing includes standard legal disclaimers stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated. The company explicitly states it does not assume any obligation to update the information in the future. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K form itself.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 Press Release, as they are absent from the 8-K text.
- Confirm the company name is Imprimis Pharmaceuticals, Inc. (Delaware), noting the discrepancy with the "Harrow, Inc." label in the request metadata.
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are typical drivers for this biopharmaceutical company.
- Check subsequent filings for any updates to the financial data, as the company disclaims an obligation to update this specific report.